Sun Pharma Stock Slumps 2% After USFDA Issuer Warning Letter For Dadra Facility
Besides, Sun Pharma informs about its 32nd Annual General Meeting (AGM) which will be held on 05 August to approve final dividend
Sun Pharma stocks slumped over 2 per cent in the Thursday trading session after the United States Foods and Drug Administration (USFDA) issued a warning letter for its Dadra facility.
Sun Pharma stocks dipped 1.97 per cent to Rs 1,474 in the afternoon session on the National Stock Exchange (NSE).
“This is to inform that the Company has received a warning Letter from USFDA for its Dadra facility. This intimation is further to our communication dated 11 April 2024, about Dadra facility receiving OAI status by the USFDA,” stated Sun Pharma in an exchange filing.
The warning letter summarised violations with respect to current good manufacturing practice (cGMP) regulations.
Company further stated that the contents of the warning letter shall be made public by the USFDA in due course.
Besides, Sun Pharma informed about its 32nd Annual General Meeting (AGM) which will be held on Monday, 05 August.
Additionally, record date and payment of final dividend for FY 2023-24 is fixed at 12 July 2024. Eligible shareholders will receive a final dividend of Rs 5 per equity share, which, if approved at the AGM, shall be paid on or before 16 August 2024.
